Key facts
- This page summarizes Carlyle Group Inc.'s Form 4 filing for Ortho Clinical Diagnostics Holdings plc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 31 May 2022, 16:30.
Carlyle Group Inc. - 27 May 2022 Form 4 Insider Report for Ortho Clinical Diagnostics Holdings plc
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 27 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 May 2022, 16:30:28 UTC
- Prior SEC filing
- 22 Apr 2022
- Next SEC filing
- 11 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- The Carlyle Group Inc., By: /s/ Anne Frederick, Attorney-in-fact for Curtis L. Buser, Managing Director and Chief Financial Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Carlyle Group Inc. filed Form 4 for Ortho Clinical Diagnostics Holdings plc on 31 May 2022.
Change
- Previous filing in this sequence was filed on 22 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCDX
transaction
Ordinary Shares, $0.00001 par value
Disposed to Issuer
- Transaction value
- Shares
- -118,106,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 May 2022
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Carlyle Group Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time, each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash.
Footnote F2
Reflects ordinary shares held of record by Carlyle Partners VI Cayman Holdings, L.P. (the "Carlyle Investor"). The Carlyle Group Inc., a publicly traded company listed on Nasdaq, is the sole member of Carlyle Holdings II GP L.L.C., which is the managing member of Carlyle Holdings II L.L.C., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the general partner of TC Group Cayman Investment Holdings, L.P., which is the general partner of TC Group Cayman Investment Holdings Sub L.P., which is the sole member of TC Group VI Cayman, L.L.C., which is the general partner of TC Group VI Cayman, L.P., which is the general partner of the Carlyle Investor.
Footnote F3
Voting and investment determinations with respect to the ordinary shares held of record by the Carlyle Investor are made by an investment committee of TC Group VI Cayman, L.P. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by the Carlyle Investor. Each of them disclaims beneficial ownership of such securities.